Search clinical trials for: Insulin Peglispro

Total 2788 results

Eli Lilly and Company

Completed

A Study of Insulin Peglispro in Healthy Male Japanese Participants

Healthy Volunteers

Japan
Eli Lilly and Company

Completed

A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue

Diabetes Mellitus, Type 1

Austria
Eli Lilly and Company

Completed

A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Denmark
Eli Lilly and Company

Completed

A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes (IMAGINE 8)

Type 2 Diabetes Mellitus

Germany, United States
Eli Lilly and Company

Completed

A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus (IMAGINE 7)

Type 1 Diabetes Mellitus

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Withdrawn

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus (IMAGINE 5)

Diabetes Mellitus, Type 2

United States, Germany, Israel, Czechia, Spain, Russian Federation, Romania, Puerto Rico, Greece
Eli Lilly and Company

Completed

A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements

Diabetes Mellitus, Type 1

Germany
Eli Lilly and Company

Completed

A Study in Participants With Type 2 Diabetes Mellitus (IMAGINE 4)

Diabetes Mellitus, Type 2

Israel, Italy, Russian Federation, Turkey, Japan, Czechia, Spain, United Kingdom, United States, Australia, Hungary, Puerto Rico, Mexico, Austria, Germany, Denmark, Croatia, Greece, Romania, Taiwan, Brazil, Netherlands, Poland, Lithuania and more
Eli Lilly and Company

Completed

A Study of LY3192767 in Healthy Participants

Healthy

Germany
Eli Lilly and Company

Completed

A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

Type 2 Diabetes Mellitus

Japan, Taiwan, Korea, Republic of
Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (SPIRIT)

Type 2 Diabetes Mellitus

Ukraine
Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Austria, Switzerland, United Kingdom, Germany, Ireland
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Novo Nordisk A/S

Completed

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, Norway
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Novo Nordisk A/S

Completed

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (PreFER)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Germany, Switzerland
Novo Nordisk A/S

Completed

Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes

Italy
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
CPEX Pharmaceuticals Inc.

Completed

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus (CPEX-011)

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
CPEX Pharmaceuticals Inc.

Withdrawn

Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland
Novo Nordisk A/S

Completed

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

Diabetes Mellitus, Type 2 | Diabetes

Morocco, Tunisia, Algeria, South Africa, Egypt
Novo Nordisk A/S

Completed

Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
IKFE Institute for Clinical Research and Development

Completed

Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes

Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Canada, Australia
Novo Nordisk A/S

Completed

Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation, Ukraine
Novo Nordisk A/S

Completed

Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes (REACH)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom

3

Subscribe